Thursday, May 15, 2014
Asthma is notoriously difficult to accurately diagnose
because its symptoms can be transient and common tests are susceptible to user
error. A University of Wisconsin-Madison
team believes that it can improve the process by using a microfluidic device
that analyzes the mobility of inflammatory cells contained in a single drop of
Although the University of Wisconsin-Madison team found that the
device can discriminate between patients with asthma and allergic rhinitis, a
key next step for the team is to determine whether the device can also
differentiate between asthma and other inflammatory diseases, such as chronic
obstructive pulmonary disease (COPD).
Although the researchers are moving forward with the
asthma diagnostic indication, Salus' initial plans for commercial development
are in the R&D tool space, in which products can be brought to market
Martz, L. SciBX 7(19);
Published online May 15, 2014
1. Sackmann, E.K.-H et al. Proc. Natl. Acad. Sci. USA;
published online April 7, 2014; doi:10.1073/pnas.1324043111
Contact: David J. Beebe, University of Wisconsin-Madison,
2. Fahy, J.V. Proc. Am. Thorac. Soc. 6, 256-259 (2009)
3. Wenzel, S.E. et al. Am. J. Respir. Crit. Care Med. 156, 737-743 (1997)
4. Sackmann, E.K. et al. Blood 120,
5. Berthier, E. et al. Lab Chip 13,
AND INSTITUTIONS MENTIONED
Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland
Salus Discovery LLC, Madison, Wis.
University of Ottawa, Ottawa, Ontario, Canada
University of Wisconsin-Madison, Madison, Wis.
Wisconsin Alumni Research Foundation, Madison, Wis.